




FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

MARK B. WILSON
PARTNER
MBWILSON@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3035
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

February 8, 2005

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below: *	
February 8, 2005	
Date	Mark B. Wilson

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/669,161 entitled "METHODS FOR VACCINE IDENTIFICATION AND COMPOSITIONS FOR VACCINATION COMPRISING NUCLEIC ACID AND/OR POLYPEPTIDE SEQUENCES OF THE HERPESVIRUS FAMILY" – by Kathryn F. Sykes, et al.,*
Our reference: MCRO:002US
U.T. Ref. UTSD:0833

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references A3-A7 and C19-C20.

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/MCRO:002US.


Commissioner for Patents

February 8, 2005

Page 2

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'MBW', written over the typed name.

Mark B. Wilson

Reg. No. 37,259

MBW/msn

Encl: as noted

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Application of:

Kathryn F. Sykes, *et al.*,

Serial No.: 10/669,161

Filed: September 23, 2003

For: METHODS FOR VACCINE
IDENTIFICATION AND
COMPOSITIONS FOR VACCINATION
COMPRISING NUCLEIC ACID AND/OR
POLYPEPTIDE SEQUENCES OF THE
HERPESVIRUS FAMILY



Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: MCRO:002US

**CERTIFICATE OF MAILING
37 C.F.R. 1.8**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date below:

February 8, 2005

Date

Mark B. Wilson

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/MCRO:002US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Mark B. Wilson
Reg. No. 37,259
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: February 8, 2005

Form PTO-1449 (modified)

Atty. Docket No.

MCRO:002US

Serial No.

10/669,161

List of Patents and Publications for Applicant's

Applicant

Kathryn F. Sykes *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 23, 2003

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A3	4,891,315	01/02/90	Watson, <i>et al.</i> ,	435	69.3	07/06/83
	A4	5,151,267	09/29/92	Babiuk, <i>et al.</i> ,	424	89	07/15/88
	A5	5,679,348	10/21/97	Nesburn, <i>et al.</i> ,	424	186.1	02/03/92
	A6	5,747,039	05/05/98	Burke, <i>et al.</i> ,	424	186.1	02/08/95
	A7	5,750,114	05/12/98	Burke, <i>et al.</i> ,	424	231.1	05/30/95

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C19.	Dolan, <i>et al.</i> , "Statues of the ICP34.5 gene in herpes simplex virus type 1 strain 17," <i>J. Gen. Virol.</i> , 73:971-973, 1992.
	C20.	Perry and McGeoch, "The DNA sequences of the long repeat region and adjoining parts of the long unique region in the genome of herpes simplex virus type 1," <i>J. Gen. Virol.</i> , 69:2831-2846, 1988.

25500018.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.